Aseptic excellence Nova-Tech operates a state-of-the-art 85,000-square-foot aseptic fill facility with two level 100 filling suites, indicating strong capabilities for high-purity parenteral injectable manufacturing suitable for expansion into additional animal health product lines or contract manufacturing for larger partners.

Recall readiness Recent voluntary recall of a Lactated Ringers lot highlights a potential quality risk; this creates opportunities to offer enhanced QA/QC services, batch traceability solutions, and risk mitigation programs to customers seeking robust regulatory compliance and recall-prevention strategies.

Growth capital With revenue in the mid-range and backing from investors, there may be appetite for scale-up partnerships, capacity expansion projects, or co-manufacturing arrangements with larger animal health players seeking reliable parenteral fill capacity.

Strategic leadership Leadership appointment of a new CEO in 2019 and ongoing growth focus signal a readiness to pursue strategic partnerships, technology upgrades, and customer-centric service models that align with large-scale pharma and biotech distributors seeking dependable injectable manufacturing.

Industry positioning As one of the largest FDA-registered parenteral injectable manufacturers for animal health in the U.S., Nova-Tech can target mid-to-large animal health brands and contract manufacturers looking for compliant, high-safety manufacturing capabilities and potential long-term supply agreements.